Literature DB >> 23066330

Penicillium marneffei chylous ascites in acquired immune deficiency syndrome: a case report.

Yin-Zhong Shen1, Zhen-Yan Wang, Hong-Zhou Lu.   

Abstract

Penicillium marneffei (P. marneffei) infection usually occurs with skin, bone marrow, lung or hepatic involvement. However, no cases of P. marneffei infection with chylous ascites have been reported thus far. In this report, we describe the first case of acquired immune deficiency syndrome (AIDS) which has been complicated by a P. marneffei infection causing chylous ascites. We describe the details of the case, with an emphasis on treatment regimen. This patient was treated with amphotericin B for 3 mo, while receiving concomitant therapy with an efavirenz-containing antiretroviral regimen, but cultures in ascitic fluid were persistently positive for P. marneffei. The infection resolved after treatment with high-dose voriconazole (400 mg every 12 h) for 3 mo. P. marneffei should be considered in the differential diagnosis of chylous ascites in human immunodeficiency virus patients. High-dose voriconazole is an effective, well-tolerated and convenient option for the treatment of systemic infections with P. marneffei in AIDS patients on an efavirenz-containing antiretroviral regimen.

Entities:  

Keywords:  Acquired immune deficiency syndrome; Chylous ascites; Efavirenz; Fungal sepsis; Penicillium marneffei; Voriconazole

Mesh:

Substances:

Year:  2012        PMID: 23066330      PMCID: PMC3468868          DOI: 10.3748/wjg.v18.i37.5312

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  15 in total

1.  Penicilliosis in China.

Authors:  S S Y Wong; K Y Yuen
Journal:  Mycopathologia       Date:  2004-08       Impact factor: 2.574

2.  Fifteen cases of penicilliosis in Guangdong, China.

Authors:  Xi Liyan; Lu Changming; Zhou Xianyi; Wang Luxia; Xie Suisheng
Journal:  Mycopathologia       Date:  2004-08       Impact factor: 2.574

Review 3.  Penicillium marneffei infection and recent advances in the epidemiology and molecular biology aspects.

Authors:  Nongnuch Vanittanakom; Chester R Cooper; Matthew C Fisher; Thira Sirisanthana
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

4.  Voriconazole therapeutic drug monitoring.

Authors:  J Smith; N Safdar; V Knasinski; W Simmons; S M Bhavnani; P G Ambrose; D Andes
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

Review 5.  Disseminated Penicillium marneffei infection in an HIV-positive Italian patient and a review of cases reported outside endemic regions.

Authors:  Spinello Antinori; Erika Gianelli; Carmen Bonaccorso; Anna Lisa Ridolfo; Francesco Croce; Salvatore Sollima; Carlo Parravicini
Journal:  J Travel Med       Date:  2006 May-Jun       Impact factor: 8.490

6.  Breakthrough Candida infections in patients receiving voriconazole.

Authors:  Lana Gerzenshtein; Shilpa M Patel; Kimberly K Scarsi; Michael J Postelnick; John P Flaherty
Journal:  Ann Pharmacother       Date:  2005-05-24       Impact factor: 3.154

7.  Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.

Authors:  Andres Pascual; Thierry Calandra; Saskia Bolay; Thierry Buclin; Jacques Bille; Oscar Marchetti
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

8.  Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders.

Authors:  Koki Ueda; Yasuhito Nannya; Keiki Kumano; Akira Hangaishi; Tsuyoshi Takahashi; Yoichi Imai; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2009-04-02       Impact factor: 2.490

9.  Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens.

Authors:  K Supparatpinyo; K E Nelson; W G Merz; B J Breslin; C R Cooper; C Kamwan; T Sirisanthana
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

10.  Voriconazole as therapy for systemic Penicillium marneffei infections in AIDS patients.

Authors:  Khuanchai Supparatpinyo; Haran T Schlamm
Journal:  Am J Trop Med Hyg       Date:  2007-08       Impact factor: 2.345

View more
  1 in total

1.  Retrospective analysis of 15 cases of Penicilliosis marneffei in a southern China hospital.

Authors:  Fengli Zhou; Xiaogang Bi; Xiaoling Zou; Zhiyang Xu; Tiantuo Zhang
Journal:  Mycopathologia       Date:  2014-04-09       Impact factor: 3.785

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.